D. Anderson, E. Maraskovsky, W. Billingsley, W. Dougall, M. Tometsko et al., A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, vol.390, issue.6656, pp.175-179, 1997.
DOI : 10.1038/36593

W. Chiou, J. Liao, C. Huang, and C. Chen, 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes, British Journal of Pharmacology, vol.282, issue.2, pp.321-335, 2010.
DOI : 10.1111/j.1476-5381.2010.00823.x

W. Dougall, Osteoclast-dependent and-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis, Clin Cancer Res, 2011.

P. Hadji, Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. Critical reviews in oncology, hematology, vol.80, issue.2, pp.301-313, 2011.

. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, vol.29, issue.9, pp.1125-1132

S. Jana and G. Shekhawat, Critical review on medicinally potent plant species: Gloriosa superba, Fitoterapia, vol.82, issue.3, pp.293-301, 2011.
DOI : 10.1016/j.fitote.2010.11.008

A. Ketenci, H. Basat, and S. Esmaeilzadeh, The efficacy of topical thiocolchicoside (Muscoril) in the treatment of acute cervical myofascial pain syndrome: a single-blind, randomized, prospective, phase IV clinical study, Agri, vol.21, issue.3, pp.95-103, 2009.

S. Reuter, S. Gupta, K. Phromnoi, and B. Aggarwal, Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug, British Journal of Pharmacology, vol.281, issue.7, 2011.
DOI : 10.1111/j.1476-5381.2011.01702.x